Please find attached financial results for quarter ended 30th June, 2026

23rd July, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Bandra Kurla Complex Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026 Dear Sir / Madam, Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today i.e., 23rd July, 2026, has inter‐alia approved the unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026. In this regard, please find enclosed the following for the quarter ended 30th June, 2026: • Unaudited financial results (standalone and consolidated) as per Indian Accounting Standards; and • Limited review report (standalone and consolidated) issued by M/s B S R & Co. LLP, Statutory Auditors of the Company The Board meeting of the Company commenced today at 09:15 a.m. (IST) and is still in progress. The conclusion time of meeting will be separately intimated to the Stock Exchanges upon completion of proceedings. The above-mentioned documents will also be available on the Company’s website www.cipla.com in the Investors Section. Kindly take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: As above Prepared by: Neelam Padwad Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 (₹ in Crores) Quarter ended Year ended 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Particulars Audited Unaudited Unaudited Audited (Refer Note 10) 1. Revenue from operations a) Revenue from sale of products (refer note 9) 7,077.02 6,464.26 6,837.04 27,711.69 b) Other operating revenue 42.26 76.94 120.43 450.90 Total revenue from operations 7,119.28 6,541.20 6,957.47 28,162.59 2. Other income 210.90 148.16 258.56 882.01 3. Total income (1+2) 7,330.18 6,689.36 7,216.03 29,044.60 4. Expenses a) Cost of materials consumed 1,356.93 1,382.15 1,469.35 5,841.62 b) Purchases of stock-in-trade 1,251.70 1,284.73 1,025.02 4,451.37 c) Changes in inventories of finished goods, 58.55 (418.20) (323.66) (743.88) work-in-progres and stock-in-trade d) Employee benefits expense 1,497.41 1,414.25 1,312.30 5,366.33 e) Finance costs 17.03 13.13 14.05 54.39 f) Depreciation, impairment and amortisation expense 304.24 382.92 252.72 1,210.98 g) Impairment of investment in associates (refer note 7) - 42.02 - 42.02 h) Other expenses (refer note 9) 1,762.39 1,881.30 1,696.32 7,322.23 Total expenses 6,248.25 5,982.30 5,446.10 23,545.06 5. Profit before exceptional items, tax and share of profit/(loss) from 1,081.93 707.06 1,769.93 5,499.54 associates (3-4) 6. Exceptional item - (Loss) (refer note 4) - - - ( 275.91) 7. Profit before tax and share of profit/(loss) from associates (5+6) 1,081.93 707.06 1,769.93 5,223.63 8. Tax expense/ (credit) (net) a) Current tax 392.78 282.17 529.55 1,440.95 b) Deferred tax (97.95) (125.22) (51.67) (87.11) Total tax expense (net) 294.83 156.95 477.88 1,353.84 9. Net profit after tax before share of profit/(loss) from associates (7-8) 787.10 550.11 1,292.05 3,869.79 10. Share of profit (+)/loss (-) of associates (1.55) (7.60) (0.44) (8.05) 11. Net profit for the period/year (9+10) 785.55 542.51 1,291.61 3,861.74 12. Profit for the period/year attributable to a) Owners of the parent 789.05 554.64 1,297.62 3,879.23 b) Non - controlling interest (3.50) (12.13) (6.01) (17.49) 13. Other comprehensive income/(loss) for the period/year a) (i) Items that will not be reclassified to profit or loss 24.25 (177.96) (8.54) (188.93) (ii) Income tax on items that will not be reclassified to profit or loss (6.10) (0.69) 2.15 2.07 b) (i) Items that will be reclassified to profit or loss 188.74 301.97 86.09 828.14 (ii) Income tax on items that will be reclassified to profit or loss (12.83) 12.47 1.71 46.46 Total other comprehensive income/(loss) for the period/year 194.06 135.79 81.41 687.74 14. Total comprehensive income for the period/year (11+13) 979.61 678.30 1,373.02 4,549.48 15. Total comprehensive income/(loss) attributable to a) Owners of the parent 982.62 692.07 1,378.82 4,567.92 b) Non - controlling interest (3.01) (13.77) (5.80) (18.44) 16. Paid-up equity share capital (face value of ₹ 2/- each) (refer note 3) 161.57 161.56 161.55 161.56 17. Other equity 3 4,270.39 18. Earnings per equity share (face value of ₹ 2/- each) a) Basic (₹) *9.77 *6.87 *16.07 48.03 b) Diluted (₹) *9.76 *6.86 *16.06 48.00 *Not Annualised Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 1/ 3 1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of ₹ 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. Post 2003, the Company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be h [Showing first 8,000 characters — download PDF for full document]